Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Often used for:
Inotuzumab is a type of medicine called a monoclonal antibody. This medicine works by attaching to a protein called CD22 found on some types of leukemia cells. When inotuzumab attaches to cells with CD22, it delivers a chemotherapy medicine called calicheamicin into the cell. Inotuzumab is considered a targeted therapy because the medicine is specific to certain cell features and “targets” those cells.
Blood pressure, heart rate, breathing, and temperature will be checked regularly during and after the infusion to watch for infusion-related side effects.
Patients will have regular blood draws to check blood counts and monitor liver function. Heart function may also be monitored.
Given as a liquid into a vein by IV
Not all patients who take inotuzumab will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Possible late effects due to inotuzumab include:
Be sure to discuss these and other recommendations with your doctor or pharmacist.